Metavia Inc (MTVA) Stock Price, Quote & News

Latest News on MTVA

Mar 20, 2025, 7:31 AM EDT - 14 days ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025, 8:05 AM EST - 2 months ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Nov 18, 2024, 8:01 AM EST - 4 months ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 5 months ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 5 months ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 8:01 AM EST - 5 months ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 6 months ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 6 months ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 7 months ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:01 AM EDT - 8 months ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:01 AM EDT - 8 months ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 8 months ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024, 8:01 AM EDT - 8 months ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024, 8:01 AM EDT - 9 months ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024, 9:06 AM EDT - 10 months ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Jun 25, 2024, 5:08 PM EDT - 10 months ago

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 24, 2024, 8:01 AM EDT - 10 months ago

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 22, 2024, 8:01 AM EDT - 10 months ago

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

May 22, 2024, 8:01 AM EDT - 11 months ago

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 9, 2024, 8:01 AM EDT - 11 months ago

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 17, 2024, 8:05 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 28, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Feb 29, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 12, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

Feb 1, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Jan 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Jan 9, 2024, 8:30 AM EST - 1 year ago

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

Jan 2, 2024, 8:01 AM EST - 1 year ago

NeuroBo to Participate in Industry and Investor Conferences in January

Dec 28, 2023, 8:45 AM EST - 1 year ago

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Dec 19, 2023, 8:43 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Dec 1, 2023, 8:31 AM EST - 1 year ago

NeuroBo to Participate in Investor Conferences in December

Nov 13, 2023, 4:05 PM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 8:05 AM EST - 1 year ago

NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.

Oct 17, 2023, 8:01 AM EDT - 1 year ago

NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Sep 15, 2023, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

Aug 14, 2023, 8:01 AM EDT - 1 year ago

NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT

Aug 9, 2023, 4:05 PM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

Aug 2, 2023, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01

Jun 27, 2023, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models

Jun 13, 2023, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions

May 12, 2023, 8:00 AM EDT - 2 years ago

NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors

May 2, 2023, 8:01 AM EDT - 2 years ago

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

Apr 3, 2023, 8:00 AM EDT - 2 years ago

NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

Mar 30, 2023, 4:40 PM EDT - 2 years ago

NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results

Jan 18, 2023, 8:00 AM EST - 2 years ago

Market Cap	13.33M
Revenue (ttm)	0.00
Net Income (ttm)	-27.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	77,900
Avg Vol	23,972
Day's Range	N/A - N/A
Shares Out	8.66M
Stochastic %K	56%
Beta	0.22
Analysts	Strong Sell
Price Target	$16.00